Hey Learner, this really isn’t a big deal imo, no need for posts on stopping discussion, at the end of the day, it’s just a bit of entertainment for readers—takes a couple of minutes to skim through, and if you’re not interested, just scroll past. No harm, no foul. In fact, disagreements are healthy—they keep us from living in an echo chamber and help us see things from all angles.
And let’s be real these side discussions don’t take anything away from ATH. If there was something new to talk about with ATH fundamentals, it’d be front and center, and the off-topic stuff would naturally fade. But there isn’t anything otherwise it would be posted, so in the meantime, these conversations keep attention on ATH (which, honestly, is a net positive for the stock).
Now, if we’re talking ATH—if you believe in the science and its future, this is a massive opportunity. A Phase 2 success in a field that could generate billions in revenue, yet sitting at just a $60 million valuation?
If that’s not an opportunity, I don’t know what is.
If you truly back ATH, how does a company with strong science and a solid cash position trade below EV? With the capital from the raise (which looks set to be approved), ATH will be cash-backed and well-positioned from 0.009. Right now, there are prime entry points—if you can get in under 1.1, you’re beating the sophs who participated, with a clear view of all the upside.
That’s the play imo, turning management’s screw-up here into your opportunity. In a well-run scenario, you wouldn’t have this shot at the ground floor. But here we are so there are silver linings.
Hope some people walk away with life-changing gains from managements misstep.
ATH Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)